1st May 2024
Pharmac has announced that currently no new patients can be started on funded dulaglutide (Trulicity) or liraglutide (Victoza). People with diabetes can still self-fund these medications, but unfortunately they are expensive. Empagliflozin (Jardiance or Jardiamet in combination with metformin) is usually the best alternative if no contraindications. People with diabetes already on dulaglutide and liraglutide can continue to have them prescribed, but many pharmacies are dispensing these medications weekly due to supply shortage. NZSSD is continuing to strongly advocate that the halt on prescribing for new patients is as short as possible due to the benefits for our high-risk whaanau with diabetes. We will keep you updated and always recommend best practice wherever possible.
The NZSSD has developed national up to date and evidence-based guidance for the management of type 2 diabetes in adults with support of the Ministry of Health. The guidance is designed as a concise pragmatic resource for all health professionals working with people with type 2 diabetes in New Zealand and will be updated as evidence and practice changes.
How to navigate the guidance documents: The management and insulin algorithms below are the overarching documents for the guidance. Clicking on the blue text will take you to that relevant section and clicking on underlined text will open up further information in a text box. Please note that currently the guidance does not cover the management of type 2 diabetes in children or other types of diabetes (including type 1 diabetes) in adults.
Please use the links below for summaries of changes in the guidance: